A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)

Investigation of the Potential Effects of Pharmacologic Agents on Young Onset- Colorectal Cancer

This study will collect biospecimens (including blood, tissue, and stool samples) and health information to create a database-a type of collection of information-for better understanding young onset colorectal cancer (YOCRC). The study will include both people with YOCRC and healthy people.

Inclusion Criteria:

CRC Cohort:

• 18-49 years old
• Histological or cytological diagnosis of colorectal adenocarcinoma
• Planned CRC resection biopsy, or colonoscopy ,including surveillance colonoscopies and/or have already undergone prior surgical resection, with tissue, including normal colonic mucosae distant from the malignant tumor (only patients providing tissue sample)
• Enrollment in IRB# 20-315, Young Onset Gastrointestinal Cancer Prospective Registry (Andrea Cercek, PI)

Healthy Control Cohort:

• 18-49 years old at time of diagnosis
• Scheduled for standard-of-care colonoscopy at MSK
• Underwent surgical resection of a traumatic injury to the colon at Shaare Zedek Medical Center (SZMC)

Exclusion Criteria:

• CRC Cohort:
• Antibiotic use within 6 months of collection of stool for gut microbiome analysis s (only patients providing stool sample)
• Known inherited cancer susceptibility gene
• History of inflammatory bowel disease

Healthy Control Cohort:

• Antibiotic use within 6 months of collection of stool for gut microbiome analysis (only patients providing stool sample)
• History of or prior treatment for cancer ≤ 5 years prior to registration. Exceptions include non-melanoma skin cancer, ductal carcinoma in situ, bladder carcinoma in situ, or carcinoma-in-situ of the cervix.
• Colonoscopy for indications of IBD, anemia and/or genetic predisposition (only patients providing tissue sample).